Vaxart, Inc.

Vaxart, Inc. is a biotechnology and healthcare startup founded in 2004 with the slogan "The pill that moves the needle." The company is revolutionizing vaccine delivery methods by developing oral vaccine pills, marking a significant departure from the traditional intramuscular injection method that has been in use for two hundred years. Vaxart's innovative approach aims to target mucosal areas such as the mouth, nose, and gut to trigger robust IgA and T-cell responses, effectively combating viral invaders at their point of entry into the body.

The company has made remarkable progress, initiating Phase II trials for its oral COVID-19 vaccine and Norovirus vaccine, making it the only company globally to reach this advanced stage in developing a COVID-19 vaccine pill. In January 2024, Vaxart secured a significant $10.00MPost-IPO Equity investment from RA Capital Management, underscoring investor confidence in the groundbreaking work being carried out by the company.

With its headquarters in the United States, Vaxart, Inc. is poised to disrupt the vaccine industry and make a lasting impact on global healthcare with its novel approach to vaccine administration.